<author><surname>Barrios</surname> <given-names>V</given-names> </author><author><surname>Escobar</surname> <given-names>C</given-names> </author><author><surname>Calder&#243;n</surname> <given-names>A</given-names> </author><author><surname>Llisterri</surname> <given-names>JL</given-names> </author><author><surname>Alegr&#237;a</surname> <given-names>E</given-names> </author><author><surname>Mu&#241;iz</surname> <given-names>J</given-names> </author><title>Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis</title><source>J Cardiometab Syndr</source><year>2007</year><volume>2</volume><fpage>9</fpage><lpage>15</lpage>
<author><surname>Schillaci</surname> <given-names>G</given-names> </author><author><surname>Pirro</surname> <given-names>M</given-names> </author><author><surname>Vaudo</surname> <given-names>G</given-names> </author><author><surname>Gemelli</surname> <given-names>F</given-names> </author><author><surname>Marchesi</surname> <given-names>S</given-names> </author><author><surname>Porcellati</surname> <given-names>C</given-names> </author><title>Prognostic value of the metabolic syndrome in essential hypertension</title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>1817</fpage><lpage>1822</lpage>
<author><surname>Liu</surname> <given-names>SJ</given-names> </author><author><surname>Guo</surname> <given-names>ZR</given-names> </author><author><surname>Hu</surname> <given-names>XS</given-names> </author><author><surname>Wu</surname> <given-names>M</given-names> </author><author><surname>Chen</surname> <given-names>FM</given-names> </author><author><surname>Kang</surname> <given-names>GD</given-names> </author><title>Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up</title><source>Diabetes Res Clin Pract</source><year>2008</year><volume>81</volume><fpage>117</fpage><lpage>123</lpage>
<author><surname>Elliott</surname> <given-names>WJ</given-names> </author><author><surname>Meyer</surname> <given-names>PM</given-names> </author><title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>201</fpage><lpage>207</lpage>
<author><surname>Bakris</surname> <given-names>GL</given-names> </author><title>Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker</title><source>J Clin Hypertens</source><year>2008</year><volume>10</volume><fpage>27</fpage><lpage>32</lpage>
<author><surname>Mancia</surname> <given-names>G</given-names> </author><author><surname>Laurent</surname> <given-names>S</given-names> </author><author><surname>Agabiti-Rosei</surname> <given-names>E</given-names> </author><author><surname>Ambrosioni</surname> <given-names>E</given-names> </author><author><surname>Burnier</surname> <given-names>M</given-names> </author><author><surname>Caulfield</surname> <given-names>MJ</given-names> </author><title>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</title><source>Blood Press</source><year>2009</year><volume>18</volume><fpage>308</fpage><lpage>347</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Hewkin</surname> <given-names>A</given-names> </author><author><surname>Kipnes</surname> <given-names>M</given-names> </author><author><surname>Sarafidis</surname> <given-names>P</given-names> </author><author><surname>Fakouhi</surname> <given-names>K</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><author><surname>Sowers</surname> <given-names>J</given-names> </author><title>STAR investigators. differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome</title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2592</fpage><lpage>2597</lpage>
<author><surname>Kintscher</surname> <given-names>U</given-names> </author><author><surname>Bramlage</surname> <given-names>P</given-names> </author><author><surname>Paar</surname> <given-names>WD</given-names> </author><author><surname>Thoenes</surname> <given-names>M</given-names> </author><author><surname>Unger</surname> <given-names>T</given-names> </author><title>Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two-armed study in 14&#8201;200 patients</title><source>Cardiovasc Diabetol</source><year>2007</year><volume>6</volume><fpage>12</fpage>
<author><surname>Heidemann</surname> <given-names>C</given-names> </author><author><surname>Sun</surname> <given-names>Q</given-names> </author><author><surname>van Dam</surname> <given-names>RM</given-names> </author><author><surname>Meigs</surname> <given-names>JB</given-names> </author><author><surname>Zhang</surname> <given-names>C</given-names> </author><author><surname>Tworoger</surname> <given-names>SS</given-names> </author><title>Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women</title><source>Ann Intern Med</source><year>2008</year><volume>149</volume><fpage>307</fpage><lpage>316</lpage>
<author><surname>Sj&#246;holm</surname> <given-names>A</given-names> </author><author><surname>Nystr&#246;m</surname> <given-names>T</given-names> </author><title>Inflammation and the etiology of type 2 diabetes</title><source>Diabetes Metab Res Rev</source><year>2006</year><volume>22</volume><fpage>4</fpage><lpage>10</lpage>
<author><surname>Rubin</surname> <given-names>D</given-names> </author><author><surname>Claas</surname> <given-names>S</given-names> </author><author><surname>Pfeuffer</surname> <given-names>M</given-names> </author><author><surname>Nothnagel</surname> <given-names>M</given-names> </author><author><surname>Foelsch</surname> <given-names>UR</given-names> </author><author><surname>Schrezenmeir</surname> <given-names>J</given-names> </author><title>s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal</title><source>Lipids Health Dis</source><year>2008</year><volume>7</volume><fpage>32</fpage>
<author><surname>Fabia</surname> <given-names>MJ</given-names> </author><author><surname>Abdilla</surname> <given-names>N</given-names> </author><author><surname>Oltra</surname> <given-names>R</given-names> </author><author><surname>Fernandez</surname> <given-names>C</given-names> </author><author><surname>Redon</surname> <given-names>J</given-names> </author><title>Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24&#8201;h ambulatory blood pressure monitoring</title><source>J Hypertens</source><year>2007</year><volume>25</volume><fpage>1327</fpage><lpage>1336</lpage>
<author><surname>Mason</surname> <given-names>RP</given-names> </author><author><surname>Marche</surname> <given-names>P</given-names> </author><author><surname>Hintze</surname> <given-names>TH</given-names> </author><title>Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine</title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>2155</fpage><lpage>2163</lpage>
<author><surname>Fogari</surname> <given-names>R</given-names> </author><author><surname>Preti</surname> <given-names>P</given-names> </author><author><surname>Zoppi</surname> <given-names>A</given-names> </author><author><surname>Mugellini</surname> <given-names>A</given-names> </author><author><surname>Corradi</surname> <given-names>L</given-names> </author><author><surname>Lazzari</surname> <given-names>P</given-names> </author><author><surname>Santoro</surname> <given-names>T</given-names> </author><author><surname>Derosa</surname> <given-names>G</given-names> </author><title>Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients</title><source>Intern Med</source><year>2008</year><volume>47</volume><fpage>1851</fpage><lpage>1857</lpage>
<author><surname>Alberti</surname> <given-names>KG</given-names> </author><author><surname>Zimmet</surname> <given-names>P</given-names> </author><author><surname>Shaw</surname> <given-names>J</given-names> </author><title>The metabolic syndrome-a new worldwide definition</title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1059</fpage><lpage>1062</lpage>
<author><surname>Hansson</surname> <given-names>L</given-names> </author><author><surname>Hedner</surname> <given-names>T</given-names> </author><author><surname>Dahl&#246;f</surname> <given-names>B</given-names> </author><title>Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials</title><source>Blood Press</source><year>1992</year><volume>1</volume><fpage>113</fpage><lpage>119</lpage>
<source>Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia</source><publisher>WHO: Geneva, Switzerland</publisher><year>2006</year>
<author><surname>Wallace</surname> <given-names>TM</given-names> </author><author><surname>Levy</surname> <given-names>JC</given-names> </author><author><surname>Matthews</surname> <given-names>DR</given-names> </author><title>Use and abuse of HOMA modeling</title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1487</fpage><lpage>1495</lpage>
<author><surname>Law</surname> <given-names>MR</given-names> </author><author><surname>Wald</surname> <given-names>NJ</given-names> </author><author><surname>Morris</surname> <given-names>JK</given-names> </author><author><surname>Jordan</surname> <given-names>RE</given-names> </author><title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</title><source>BMJ</source><year>2003</year><volume>326</volume><fpage>1427</fpage><lpage>1431</lpage>
<author><surname>Wald</surname> <given-names>DS</given-names> </author><author><surname>Law</surname> <given-names>M</given-names> </author><author><surname>Morris</surname> <given-names>JK</given-names> </author><author><surname>Bestwick</surname> <given-names>JP</given-names> </author><author><surname>Wald</surname> <given-names>NJ</given-names> </author><title>Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11&#8201;000 participants from 42 trials</title><source>Am J Med</source><year>2009</year><volume>122</volume><fpage>290</fpage><lpage>300</lpage>
<author><surname>Chrysant</surname> <given-names>SG</given-names> </author><author><surname>Melino</surname> <given-names>M</given-names> </author><author><surname>Karki</surname> <given-names>S</given-names> </author><author><surname>Lee</surname> <given-names>J</given-names> </author><author><surname>Heyrman</surname> <given-names>R</given-names> </author><title>The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study</title><source>Clin Ther</source><year>2008</year><volume>30</volume><fpage>587</fpage><lpage>604</lpage>
<author><surname>Punzi</surname> <given-names>HA</given-names> </author><title>Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide</title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><fpage>229</fpage><lpage>239</lpage>
<author><surname>De Pablos-Velasco</surname> <given-names>PL</given-names> </author><author><surname>Mart&#237;nez-Mart&#237;n</surname> <given-names>FJ</given-names> </author><author><surname>Rodr&#237;guez-P&#233;rez</surname> <given-names>F</given-names> </author><title>Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the Gu&#237;a Study</title><source>Eur J Clin Nutr</source><year>2002</year><volume>56</volume><fpage>557</fpage><lpage>560</lpage>
<author><surname>Borch-Johnsen</surname> <given-names>K</given-names> </author><author><surname>Wareham</surname> <given-names>N</given-names> </author><title>The rise and fall of the metabolic syndrome</title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>597</fpage><lpage>599</lpage>
<author><surname>Ninomiya</surname> <given-names>T</given-names> </author><author><surname>Kiyohara</surname> <given-names>Y</given-names> </author><title>Albuminuria and chronic kidney disease in association with the metabolic syndrome</title><source>J Cardiometab Syndr</source><year>2007</year><volume>2</volume><fpage>104</fpage><lpage>107</lpage>
<author><surname>Gerstein</surname> <given-names>HC</given-names> </author><author><surname>Mann</surname> <given-names>JF</given-names> </author><author><surname>Yi</surname> <given-names>Q</given-names> </author><author><surname>Zinman</surname> <given-names>B</given-names> </author><author><surname>Dinneen</surname> <given-names>SF</given-names> </author><author><surname>Hoogwerf</surname> <given-names>B</given-names> </author><title>Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals</title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>421</fpage><lpage>426</lpage>
<author><surname>Ibsen</surname> <given-names>H</given-names> </author><author><surname>Olsen</surname> <given-names>MH</given-names> </author><author><surname>Wachtell</surname> <given-names>K</given-names> </author><author><surname>Borch-Johnsen</surname> <given-names>K</given-names> </author><author><surname>Lindholm</surname> <given-names>LH</given-names> </author><author><surname>Mogensen</surname> <given-names>CE</given-names> </author><title>Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study</title><source>Hypertension</source><year>2005</year><volume>45</volume><fpage>198</fpage><lpage>202</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Stockert</surname> <given-names>J</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Zhou</surname> <given-names>Q</given-names> </author><author><surname>Champion</surname> <given-names>A</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><title>Risk factor assessment for new onset diabetes: literature review</title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><fpage>177</fpage><lpage>187</lpage>
<author><surname>Chobanian</surname> <given-names>AV</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><author><surname>Cushman</surname> <given-names>WC</given-names> </author><author><surname>Green</surname> <given-names>LA</given-names> </author><author><surname>Izzo</surname> <given-names>JL</given-names> <suffix>Jr</suffix> </author><title>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report</title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2560</fpage><lpage>2572</lpage>
<author><surname>Kaplan</surname> <given-names>NM</given-names> </author><title>The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide</title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>951</fpage><lpage>953</lpage>
<author><surname>Eriksson</surname> <given-names>JW</given-names> </author><author><surname>Jansson</surname> <given-names>PA</given-names> </author><author><surname>Carlberg</surname> <given-names>B</given-names> </author><author><surname>H&#228;gg</surname> <given-names>A</given-names> </author><author><surname>Kurland</surname> <given-names>L</given-names> </author><author><surname>Svensson</surname> <given-names>MK</given-names> </author><title>Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) study</title><source>Hypertension</source><year>2008</year><volume>52</volume><fpage>1030</fpage><lpage>1037</lpage>
<author><surname>Cooper-DeHoff</surname> <given-names>RM</given-names> </author><author><surname>Wen</surname> <given-names>S</given-names> </author><author><surname>Beitelshees</surname> <given-names>AL</given-names> </author><author><surname>Zineh</surname> <given-names>I</given-names> </author><author><surname>Gums</surname> <given-names>JG</given-names> </author><author><surname>Turner</surname> <given-names>ST</given-names> </author><title>Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications</title><source>Hypertension</source><year>2010</year><volume>55</volume><fpage>61</fpage><lpage>68</lpage>
<author><surname>Alderman</surname> <given-names>MH</given-names> </author><title>New-onset diabetes during antihypertensive therapy</title><source>Am J Hypertens</source><year>2008</year><volume>21</volume><fpage>493</fpage><lpage>499</lpage>
<author><surname>Alderman</surname> <given-names>MH</given-names> </author><title>Is new-onset diabetes mellitus important? Yes, but&#8230;</title><source>High Blood Pres &amp; Cardiovasc Prev</source><year>2008</year><volume>15</volume><fpage>5</fpage><lpage>8</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Zhou</surname> <given-names>Q</given-names> </author><author><surname>Sarafidis</surname> <given-names>P</given-names> </author><author><surname>Champion</surname> <given-names>A</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><title>Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study</title><source>J Cardiometab Syndr</source><year>2008</year><volume>3</volume><fpage>18</fpage><lpage>25</lpage>
<author><surname>Aguilar</surname> <given-names>D</given-names> </author><author><surname>Solomon</surname> <given-names>SD</given-names> </author><author><surname>K&#248;ber</surname> <given-names>L</given-names> </author><author><surname>Rouleau</surname> <given-names>JL</given-names> </author><author><surname>Skali</surname> <given-names>H</given-names> </author><author><surname>McMurray</surname> <given-names>JJ</given-names> </author><title>Newly diagnosed and previously known diabetes mellitus and 1&#8211;year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial</title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>1572</fpage><lpage>1578</lpage>
<author><surname>Jamerson</surname> <given-names>K</given-names> </author><author><surname>Weber</surname> <given-names>MA</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Dahl&#246;f</surname> <given-names>B</given-names> </author><author><surname>Pitt</surname> <given-names>B</given-names> </author><author><surname>Shi</surname> <given-names>V</given-names> </author><title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2417</fpage><lpage>2428</lpage>
<author><surname>Matsui</surname> <given-names>Y</given-names> </author><author><surname>Eguchi</surname> <given-names>K</given-names> </author><author><surname>O&#8242;Rourke</surname> <given-names>MF</given-names> </author><author><surname>Ishikawa</surname> <given-names>J</given-names> </author><author><surname>Miyashita</surname> <given-names>H</given-names> </author><author><surname>Shimada</surname> <given-names>K</given-names> </author><title>Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients</title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>716</fpage><lpage>723</lpage>
<author><surname>Fliser</surname> <given-names>D</given-names> </author><author><surname>Buchholz</surname> <given-names>K</given-names> </author><author><surname>Haller</surname> <given-names>H</given-names> </author><title>Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertension patients with microinflammation</title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>1103</fpage><lpage>1107</lpage>
<author><surname>Smith</surname> <given-names>DH</given-names> </author><author><surname>Neutel</surname> <given-names>JM</given-names> </author><author><surname>Lacourci&#232;re</surname> <given-names>Y</given-names> </author><author><surname>Kempthorne-Rawson</surname> <given-names>J</given-names> </author><title>Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements</title><source>J Hypertens</source><year>2003</year><volume>21</volume><fpage>1291</fpage><lpage>1298</lpage>